Core Laboratories (CLB) Cash from Financing Activities (2022 - 2026)

Core Laboratories has reported Cash from Financing Activities for 5 years, with the latest figure at -$457000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 89.8% year-over-year to -$457000.0; the trailing twelve-month figure through Mar 2026 stood at -$27.2 million (up 41.26% YoY), and the FY2025 full-year result was -$31.3 million, up 31.99% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$457000.0, up from -$7.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $6.1 million in Q1 2023, with the low at -$19.4 million in Q4 2024.
• Historically, Cash from Financing Activities has averaged -$7.6 million across 5 years, with a median of -$6.0 million in 2023.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities tumbled 32464.29% — and 2026, when it surged 89.8%.
• Core Laboratories' Cash from Financing Activities stood at -$12.6 million in 2022, then plunged by 46.97% to -$18.5 million in 2023, then decreased by 4.84% to -$19.4 million in 2024, then soared by 63.24% to -$7.1 million in 2025, then soared by 93.58% to -$457000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$457000.0 (Q1 2026), -$7.1 million (Q4 2025), and -$16.5 million (Q3 2025), per Business Quant data.